A Phase 4 interventional study of paliperidone and risperidone in Schizophrenia, sponsored by Janssen Scientific Affairs, LLC. Completed at 56 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-24.
Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 22nd largest by enrollment, is one of 8 that started in 2010, is one of 42 in phase 4, and was the 57th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 450 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 33rd largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2010, is one of 47 in phase 4, and was the 136th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.
The primary objective of this study is to compare the efficacy of paliperidone palmitate with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated. Protocol-defined treatment failure is defined as arrest, psychiatric hospitalization, increase in psychiatric services to prevent imminent hospitalization, discontinuation of antipsychotic treatment due to inadequate efficacy, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to safety or tolerability or completed suicide. Protocol was amended on March 15, 2011 to reflect changes in the inclusion/exclusion criteria as well as the study objectives. Patients will receive either paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for fifteen months OR oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the study doctor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
Drug: paliperidone palmitate
aripiprazole flexible dosing as prescribed by the study doctor for 15 months
Drug: aripiprazole
haloperidole flexible dosing as prescribed by the study doctor for 15 months
Drug: haloperidole
olanzapine flexible dosing as prescribed by the study doctor for 15 months
Drug: olanzapine
paliperidone flexible dosing as prescribed by the study doctor for 15 months
Drug: paliperidone
perphenazine flexible dosing as prescribed by the study doctor for 15 months
Drug: perphenazine
quetiapine flexible dosing as prescribed by the study doctor for 15 months
Drug: quetiapine
risperidone flexible dosing as prescribed by the study doctor for 15 months
Drug: risperidone
flexible dosing as prescribed by the study doctor for 15 months
flexible dosing as prescribed by the study doctor for 15 months
flexible dosing as prescribed by the study doctor for 15 months
flexible dosing as prescribed by the study doctor for 15 months
flexible dosing as prescribed by the study doctor for 15 months
flexible dosing as prescribed by the study doctor for 15 months
78, 117, 156, or 234 mg monthly injection for 15 months
flexible dosing as prescribed by the study doctor for 15 months
Time to First Treatment Failure
Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event.
Time frame: From date of randomization up to Month 15
Percentage of Participants in Each Event Category of First Treatment Failure
First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed.
Time frame: From date of randomization up to Month 15
Time to First Psychiatric Hospitalization or Arrest/Incarceration
A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia.
Time frame: From date of randomization up to Month 15
Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration
The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score \<=30 represents poor function that requires intensive supervision.
Time frame: Baseline up to Month 15
Time to First Psychiatric Hospitalization
A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization."
Time frame: From date of randomization up to Month 15
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration
The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness.
Time frame: Baseline up to Month 15
| Milestone | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Started | 230 | 220 |
| Treated | 226 | 218 |
| Completed | 93 | 88 |
| Not completed | 137 | 132 |
| Withdrew: Adverse event | 5 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 53 | 55 |
| Withdrew: Withdrawal by subject | 37 | 27 |
| Withdrew: Physician decision | 5 | 4 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 32 | 36 |
| Withdrew: Noncompliance with study drug | 0 | 3 |
| Withdrew: Randomized but not treated | 4 | 2 |
Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event.
| Days | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Time to First Treatment Failure | 416 (285 to NA) | 226 (147 to 304) |
A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia.
| Days | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Time to First Psychiatric Hospitalization or Arrest/Incarceration | NA (NA to NA) | 274 (202 to 407) |
The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score \<=30 represents poor function that requires intensive supervision.
| Units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration | 5.75 ± 0.690 | 5.36 ± 0.690 |
A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization."
| Days | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Time to First Psychiatric Hospitalization | NA (NA to NA) | NA (NA to NA) |
The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness.
| Units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration | -0.48 ± 0.038 | -0.43 ± 0.037 |
First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed.
| percentage of participants | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Treatment Failure Due to Any Event | 39.8 | 53.7 |
| Arrest/incarceration | 21.2 | 29.4 |
| Psychiatric hospitalization | 8.0 | 11.9 |
| D/C due to safety/tolerability | 6.6 | 3.7 |
| Treatment supplementation | 2.2 | 2.8 |
| D/C due to inadequate efficacy | 0.4 | 4.1 |
| Increase in level of psychiatric services | 1.3 | 1.8 |
| Suicide | 0 | 0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone Palmitate | — | 42/226 (18.6%) | 178/226 (78.8%) |
| Oral Antipsychotics | — | 53/218 (24.3%) | 155/218 (71.1%) |
| Event | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| SchizophreniaPsychiatric disorders | 4/226 | 11/218 |
| Suicidal IdeationPsychiatric disorders | 5/226 | 11/218 |
| Psychotic DisorderPsychiatric disorders | 11/226 | 7/218 |
| Schizophrenia, Paranoid TypePsychiatric disorders | 4/226 | 5/218 |
| DepressionPsychiatric disorders | 4/226 | 1/218 |
| Homicidal IdeationPsychiatric disorders | 0/226 | 3/218 |
| Suicide AttemptPsychiatric disorders | 1/226 | 3/218 |
| Acute PsychosisPsychiatric disorders | 1/226 | 2/218 |
| Renal Failure AcuteRenal and urinary disorders | 1/226 | 2/218 |
| CellulitisInfections and infestations | 2/226 | 1/218 |
| Event | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Injection Site PainGeneral disorders | 42/226 | 0/218 |
| InsomniaPsychiatric disorders | 42/226 | 27/218 |
| Weight IncreasedInvestigations | 30/226 | 16/218 |
| AkathisiaNervous system disorders | 26/226 | 17/218 |
| AnxietyPsychiatric disorders | 25/226 | 18/218 |
| HeadacheNervous system disorders | 17/226 | 19/218 |
| DepressionPsychiatric disorders | 19/226 | 17/218 |
| Dry MouthGastrointestinal disorders | 15/226 | 18/218 |
| SedationNervous system disorders | 15/226 | 18/218 |
| FatigueGeneral disorders | 17/226 | 6/218 |
Intent to Treat (ITT) population included all participants who were randomly assigned to treatment and who received at least 1 dose of their randomly assigned study treatment.
| Age, Continuous(years) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| Mean | 37.7 ± 10.57 | 38.6 ± 10.36 | 38.1 ± 10.47 |
| Sex: Female, Male(Participants) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| Female | 33 | 28 | 61 |
| Male | 193 | 190 | 383 |
| Baseline Personal and Social Performance (PSP) Total Score(Units on a scale) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| Mean | 54.8 ± 12.83 | 55.0 ± 12.73 | 54.9 ± 12.76 |
| Baseline Clinical Global Impression - Severity (CGI-S) Total Score(Units on a scale) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| Mean | 3.8 ± 0.80 | 3.9 ± 0.70 | 3.8 ± 0.75 |
The record gives a start of May 2010, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Scientific Affairs, LLC →